Significance of Microscopic Residual Tumor in Adenocarcinoma of Stomach and Esophagogastric Junction after Gastrectomy with D2 Lymphadenectomy

Authors

  • Thammawat Parakonthun Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Narathip Parichardsombat Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Hugo Salomon Department of Surgery, Eugenio Espejo General Hospital, Quito
  • Rosero Paredes Department of Surgery, Eugenio Espejo General Hospital, Quito
  • Chainarong Phalanusittheph Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Voraboot Taweerutchana Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Atthaphorn Trakarnsanga Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Jirawat Swangsri Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Thawatchai Akaraviputh Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Asada Methasate Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700
  • Vitoon Chinswangwatanakul Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700

Abstract

Objective: Microscopic residual tumor (R1 resection) may have a significant negative impact on prognosis of patients with adenocarcinoma of stomach and esophagogastric junction. Results of R1 resection on survival and recurrence patterns have not yet been thoroughly investigated in Thailand. The aim of this study was to study the oncological outcomes of R1 resection after curative intended surgery.
Methods: We retrospectively analyzed the medical records of patients who underwent curative intended surgery from 2005 to 2013 at Siriraj Hospital. 
Results: 162 patients underwent curative intended gastrectomy with radical lymphadenectomy. 122 (75.3%) patients received R0 resection (non-residual group), 40 (24.7%) patients had microscopic residual tumor (residual group). Microscopic residual tumor was associated with tumor size (p=0.008), tumor extension (p=0.028), pT-stage (p=0.012), pN-stage (p=0.012), and AJCC/TNM stage (p<0.001). Large tumor size (≥5 cm.) and number of metastatic lymph nodes (≥3 nodes) were the factors contributing to higher rate of microscopic residual tumor on multivariate analysis
(p=0.024 and 0.039, respectively). Median overall survival of non-residual and residual groups were 34.6 and 16.4 months (p=0.065). Median disease-free survival of non-residual and residual groups were 13.2 and 10.2 months (p=0.099). Distant metastasis was the most common site of recurrence in both groups. R1 resection was associated with worse 5-year survival rate (17.5% vs 34.0%, p=0.049).
Conclusion: Microscopic residual tumor was associated with larger tumor size and more number of metastatic lymph nodes. R1 resection resulted in worse prognosis. Distant metastasis was the most common site of recurrence, therefore, we might suggest systemic chemotherapy as an adjuvant treatment after curative intended surgery.

Downloads

Published

06-06-2018

How to Cite

Parakonthun, T., Parichardsombat, N., Salomon, H., Paredes, R., Phalanusittheph, C., Taweerutchana, V., Trakarnsanga, A., Swangsri, J., Akaraviputh, T., Methasate, A., & Chinswangwatanakul, V. (2018). Significance of Microscopic Residual Tumor in Adenocarcinoma of Stomach and Esophagogastric Junction after Gastrectomy with D2 Lymphadenectomy. Siriraj Medical Journal, 70(2), 95–102. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/127434

Issue

Vol. 70 No. 2 (2018): March-April

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.